Recent Trends in p16-Positive Oropharyngeal Squamous Cell Carcinoma in Northern Israel
This retrospective study of 130 patients in northern Israel reveals a significant temporal increase in p16-positive oropharyngeal squamous cell carcinoma from 61% to 92% over the last decade, with these HPV-associated tumors presenting at earlier stages and demonstrating significantly better five-year overall survival compared to p16-negative cases.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Cancer of the throat, specifically in the area behind the mouth known as the oropharynx, has long been associated with heavy tobacco and alcohol use. For decades, doctors understood these cancers as a consequence of lifestyle choices, affecting older adults who had smoked or drunk heavily for many years. However, a different kind of this disease has emerged in recent decades, driven not by smoke or spirits, but by a common virus called the human papillomavirus, or HPV. This viral version of the cancer tends to strike younger people who have never smoked, and it behaves differently in the body. To tell these two types apart, pathologists look for a specific protein called p16. When this protein is present in high amounts, it acts as a reliable signal that the cancer is being driven by the virus. Understanding which type of cancer a patient has is crucial because the viral kind generally responds much better to treatment and offers a much higher chance of long-term survival.
In northern Israel, a team of researchers set out to see how this global shift was playing out locally. They examined the medical records of 130 patients treated at a single major hospital between 2012 and 2024. These patients all had confirmed cases of oropharyngeal squamous cell carcinoma. The team wanted to know if the proportion of viral-driven cancers was growing in their region, just as it has in North America and Europe, and how this change affected the patients' outcomes. They carefully reviewed every detail available, from the patients' ages and smoking histories to the exact location of the tumors and the specific treatments they received.
The study revealed a dramatic transformation in the landscape of throat cancer in this region. Over the entire twelve-year period, about 72 percent of the cases were found to be p16-positive, meaning they were linked to the virus. However, this was not a static number. When the researchers looked at the earliest years of their study, from 2012 to 2016, only about 61 percent of cases were viral. By the most recent years, from 2023 to 2024, that figure had surged to 92 percent. This rapid rise mirrors the trends seen in wealthy nations across the Atlantic, suggesting that the epidemiology of throat cancer in northern Israel is shifting quickly toward a viral cause.
The characteristics of the patients and their tumors changed alongside this shift. The viral-positive patients were just as likely to be men as the non-viral patients, and their average age was similar. Yet, the location of the tumors differed significantly. The viral cancers were most often found in the tonsils, while the non-viral cancers appeared more frequently at the base of the tongue. Perhaps most importantly, the viral cancers were caught at an earlier stage of development. Patients with the viral type had smaller tumors and less spread to the lymph nodes compared to those with the non-viral type. This difference in stage was partly due to a change in how doctors classify the disease, but the underlying reality remained: the viral cancers presented in a way that was more favorable for treatment.
The treatment paths taken by these two groups also diverged. Because the non-viral cancers were often more advanced and the patients were more likely to have other health issues from smoking, doctors frequently used a different approach for them. These patients were more likely to receive induction chemotherapy, which is treatment given before the main therapy, or to receive a drug called cetuximab alongside radiation. In contrast, the viral group was more often treated with standard radiation and a different chemotherapy drug called cisplatin. The results of these treatments reflected the biology of the disease. The five-year survival rate for patients with the viral cancer was 75 percent, compared to only 47 percent for those with the non-viral cancer.
The researchers found that the combination of having a non-viral cancer and an advanced tumor stage was the strongest predictor of a poorer outcome. While the viral cancers showed a clear trend toward better survival, the non-viral group faced a steeper challenge. The study also noted that the patients with non-viral cancers included a small group who had developed a second throat cancer after previous radiation treatment, a situation that further complicated their prognosis. The team acknowledged that because this was a review of past records, they could not control exactly which treatment each patient received, which means some of the differences in survival might be influenced by how doctors chose to treat them rather than just the cancer itself.
Despite these limitations, the data paints a clear picture of a changing medical reality. The proportion of throat cancers driven by HPV in northern Israel has risen sharply, moving from a minority of cases to the overwhelming majority in just over a decade. This shift brings with it a different set of challenges and opportunities for doctors and patients. The viral cancers, while now more common, are generally less aggressive and more treatable than their non-viral counterparts. As the population continues to change, understanding these patterns helps medical teams tailor their approaches, ensuring that the right patients receive the right care at the right time. The study confirms that what was once a rare occurrence in this region has become the dominant form of the disease, aligning northern Israel with the broader global trend of HPV-driven throat cancer.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.